Truist raises Ducommun stock price target on aerospace strength By Investing.com

Truist raised Ducommun’s price target to $150 from $136 and reiterated a Buy rating, citing stronger-than-expected commercial aerospace performance and a multi-year defense growth opportunity. Q1 fiscal 2026 results were mixed, with EPS of $0.75 missing the $0.85 consensus by 11.76% while revenue beat at $209 million versus $199.65 million expected. The stock trades at $144.37 after a 113% gain over the past year, though destocking remains a near-term headwind.

Analysis

The key read-through is not the upgrade itself, but the market’s willingness to pay peak-multiple prices for a company still in the middle of an inventory digestion cycle. That combination usually works until growth inflects down again: when revenue is being pulled forward by production ramps while earnings lag from mix and working-capital drag, the next leg is often multiple compression, not earnings expansion. In other words, the stock’s recent rerating looks more like a scarcity premium on aerospace exposure than a clean fundamental rerate.

The second-order winner is likely the broader defense supply chain, but with a lag. If missile-production programs really begin scaling in 2027, the beneficiaries with more direct content or cleaner operating leverage should re-rate earlier than DCO, which is effectively being asked to bridge 6-8 quarters of near-term softness before the defense story becomes visible. That creates a window where competitors with stronger current backlog conversion can outgrow DCO on both revenue and margin, even if their top-line narratives are less exciting.

The main risk is that the market is extrapolating a future defense call that is too far out to protect the current valuation. Any evidence of prolonged destocking, weaker commercial OEM build rates, or another earnings miss would likely hit the stock harder than the recent revenue beat can cushion. This is a classic setup where the catalyst horizon is months for downside but years for the bull case, which is usually unfavorable at elevated valuation.

Contrarian take: the bullish thesis may be directionally right, but the timing is likely wrong. If investors are waiting for 2027 defense growth, they are implicitly paying today for an option that still has a long-dated payoff and near-term decay. That makes the risk/reward skew less attractive than the headline sentiment suggests, especially after a 100%+ rerating.

Key Decisions for Investors

• Fade strength in DCO: initiate a tactical short or buy puts on any post-upgrade rally; horizon 1-3 months. Risk/reward favors downside if another quarter confirms destocking, with a likely 15-25% drawdown before the 2027 defense narrative matters.
• Pair trade: long a higher-quality aerospace/defense supplier with nearer-term margin conversion vs. short DCO; use a 3-6 month horizon. The relative-value thesis is that cleaner current execution should outperform a name priced for future growth.
• If already long DCO, tighten risk with a covered call overlay 1-2 strikes out and 2-4 months to expiry. This monetizes elevated implied optimism while limiting upside participation in an overextended multiple.
• Set a catalyst watch for the next two quarters of inventory and margin data. If commercial aerospace does not reaccelerate faster than expected, reduce exposure before the market shifts from "future defense optionality" to "current execution disappointment."